We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

COVID-19 Staff Testing of Antibody Responses Study (Co-Stars) (Co-Stars)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04380896
Recruitment Status : Completed
First Posted : May 8, 2020
Last Update Posted : September 27, 2022
Sponsor:
Information provided by (Responsible Party):
Great Ormond Street Hospital for Children NHS Foundation Trust

Brief Summary:
This study will perform prospective repeated serological antibody testing on a cohort of at least 1000 healthcare workers at Great Ormond Street Hospital. Within this cohort, a subset of 150-250 staff members with confirmed (PCR positive) SARS-CoV-2 disease will be followed with intensive monthly testing for 6 months to determine whether antibody levels in the blood are maintained or decrease during this time. All 1000 recruited healthcare workers will be followed 6-monthly

Condition or disease Intervention/treatment
SARS-CoV-2 Infection Other: Blood test Other: Standardised questionnaires

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 3502 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: COVID-19 Staff Testing of Antibody Responses Study (CO-STARS)
Actual Study Start Date : April 27, 2020
Actual Primary Completion Date : July 30, 2022
Actual Study Completion Date : July 30, 2022

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
SARS-CoV-2 Seropositive Cases

It will be formed of approximately N= 200 to 350 staff members

Core Group of PCR Confirmed Cases N ~ 150 to 250:

A) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Positive N ~ 150 to 250 OR

Other SARS-CoV-2 Sero-positives N ~ 50 to 100:

B) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Negative cases. OR C) No symptoms consistent with SARS-CoV-2 infection and PCR Not Tested cases

Other: Blood test
Blood tests (8ml in total) 4ml blood for serological testing (measure the antibody titres to the SARS-CoV-2 nucleo-capsid protein (4ml) and 4ml EDTA to be stored for future research will be taken for each group.

Other: Standardised questionnaires
It will be an online questionnaire about staff members health, symptoms of SARS-CoV-2 and contact with SARS-CoV-2. All participants will also be asked to complete a detailed symptom and electronic questionnaire prior to each appointment.

SARS-CoV-2 Seronegative Comparison Group

It will be formed of approximately N= 800 to 900 staff members

Core Comparison Group N ~ 800 A) Have not had clinical symptoms consistent with SARS-CoV-2 infection OR

Other Seronegatives N ~ 100 B) Have had sympoms of SARS-CoV-2 infection but have been tested and were PCR positive or negative but have not developed antibodies at 21 days

Other: Blood test
Blood tests (8ml in total) 4ml blood for serological testing (measure the antibody titres to the SARS-CoV-2 nucleo-capsid protein (4ml) and 4ml EDTA to be stored for future research will be taken for each group.

Other: Standardised questionnaires
It will be an online questionnaire about staff members health, symptoms of SARS-CoV-2 and contact with SARS-CoV-2. All participants will also be asked to complete a detailed symptom and electronic questionnaire prior to each appointment.




Primary Outcome Measures :
  1. Change in serial monthly log-transformed antibody titre levels as measured [ Time Frame: 6 months period post infection ]
    To determine the kinetics (rate of change) of SARS-CoV-2 nucleo-capsid protein antibody titres in proven cases of SARS-CoV-2 over the 6 month period following infection


Secondary Outcome Measures :
  1. Proportion of completely asymptomatic healthcare workers with evidence of SARS-CoV-2 antibodies [ Time Frame: 12 months ]
    To determine the proportion of completely asymptomatic healthcare workers who have evidence of SARS-CoV-2 antibodies in their serum indicative of past infection

  2. The attack rate of SARS-CoV-2 in healthcare workers who have antibodies compared to those who do not [ Time Frame: Betwen 3 to 6 years ]
    To determine the attack rate of SARS-CoV-2 in healthcare workers who have antibodies versus those who do not have antibodies

  3. The immune correlates of protection against future exposure to SARS-CoV-2 [ Time Frame: Between 3 to 6 years ]
    To determine the immune correlates of protection (Antibody Titres sufficient for protection) against future exposure to SARS-CoV-2


Biospecimen Retention:   Samples With DNA

Each sample will be tested using the EDITM diagnostic assay which detects the optical density of antibodies in serum samples to the nucleo-capsid protein SARS-CoV-2. Both IgM and IgG antibodies to the nucleo-capsid protein will be tested and reported.

At the end of the study the samples will be stored at -70oC in the freezers of the Great Ormond Street Camelia Botnar Laboratories for future research. Future studies may involve genetic testing on the samples and this has been highlighted on the consent form.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The population will comprise frontline healthcare workers selected to be representative of all departments at Great Ormond Street Hospital. The researcher will ensure that equal numbers of men and women are recruited from each department and that age ranges are representative of the trust population age distribution.We will also check the age distribution of the participants on a weekly basis during recruitment against the known age distribution of the hospital to ensure that our sample is representative. If significant differences among ages between the study population and the hospital population age range emerge then we will actively recruit from those age ranges that we have inadequately sampled.
Criteria

Inclusion Criteria for ARM 1: SARS-CoV-2 Seropositive Cases:

  • Healthcare worker at GOSH
  • >18 years of age
  • ALL have confirmed detectable antibodies to SARS-CoV-2 infection on baseline screen

Then can be recruited into either of the following sub-groups

  1. Core Group of PCR Confirmed Cases : Must have symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Positive
  2. Other SARS-CoV-2 Sero-positives: May have Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Negative cases OR May have no symptoms consistent with SARS-CoV-2 infection and PCR Not Tested cases

Inclusion Criteria for ARM 2: SARS-CoV-2 Seronegative Comparison Group :

  • Healthcare worker at GOSH
  • >18 years of age
  • ALL have confirmed negative antibodies to SARS-CoV-2 infection on baseline screen

Then can be recruited into either of the following Sub-groups:

  1. Core Comparison Group: Have not had clinical symptoms consistent with SARS-CoV-2 infection*
  2. Other Seronegatives: Have had symptoms of SARS-CoV-2 infection but have been tested and were PCR positive or negative but have not developed antibodies at 21 days

    • Clinical Symptoms for SARS-CoV-2 infection are defined as one of:

1) New and persistent cough 2) Confirmed temperatures of 37.8 and above 3) Anosmia

General Exclusion Criteria :

  • <18 years of age
  • On immunosuppressive or immunomodulatory medication that may impact test reliability
  • Received any blood product including immunoglobulins after October 2019
  • Has received convalescent sera as treatment
  • Current diagnosis of a malignancy that may impact test reliability
  • Those lacking capacity to provide informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04380896


Locations
Layout table for location information
United Kingdom
Great Ormond Street Hospital
London, United Kingdom, WC1N 3JH
Sponsors and Collaborators
Great Ormond Street Hospital for Children NHS Foundation Trust
Investigators
Layout table for investigator information
Principal Investigator: Louis Grandjean, Dr Great Ormond Street Hospital NHS Foundation Trust
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Great Ormond Street Hospital for Children NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT04380896    
Other Study ID Numbers: 20CB17
First Posted: May 8, 2020    Key Record Dates
Last Update Posted: September 27, 2022
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases